Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

5-MeO-DBT

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
5-MeO-DBT
Clinical data
Other names5-OMe-DBT; 5-Methoxy-DBT; 5-Methoxy-N,N-dibutyltryptamine; 5-MeO-BET;N,N-Bu-5-MeO-T
Drug classNon-selectiveserotonin receptor agonist;Serotonin5-HT1A receptoragonist;
ATC code
  • None
Identifiers
  • N-butyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]butan-1-amine
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC19H30N2O
Molar mass302.462 g·mol−1
3D model (JSmol)
  • CCCCN(CCCC)CCC1=CNC2=C1C=C(C=C2)OC
  • InChI=1S/C19H30N2O/c1-4-6-11-21(12-7-5-2)13-10-16-15-20-19-9-8-17(22-3)14-18(16)19/h8-9,14-15,20H,4-7,10-13H2,1-3H3
  • Key:WVGCRISHWANOTO-UHFFFAOYSA-N

5-MeO-DBT, also known as5-methoxy-N,N-dibutyltryptamine, is aserotonin receptor modulator, and a raresubstituted tryptamine derivative, which is thought to be apsychoactive substance.[1][2]

Unlike many other related compounds it exhibits very lowefficacy for the5-HT2A receptor.[2]

5-MeO-DBT was first described in the literature byAlexander Shulgin in his 1997 bookTiHKAL (Tryptamines I Have Known and Loved).[1] It was identified in adesigner drug sample by a forensic laboratory inSlovenia in March 2021,[3] and assessed pharmachologically in 2023.[2] It is controlled under drug analogue legislation in a number of jurisdictions.[4]

Use and effects

[edit]

In his bookTiHKAL (Tryptamines I Have Known and Loved),Alexander Shulgin briefly mentioned 5-MeO-DBT and described it as a known compound with unknown activity.[1] Relatedly, the properties and effects of 5-MeO-DBT are unknown.[1] In any case, related drugs likedibutyltryptamine (DBT) and4-HO-DPT have been reported to yield disappointing effects.[1][5]

Interactions

[edit]
See also:Psychedelic drug § Interactions, andTrip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]
5-MeO-DBT activities
TargetAffinity (Ki, nM)
5-HT1A337 (Ki)
267 (EC50Tooltip half-maximal effective concentration)
106% (EmaxTooltip maximal efficacy)
5-HT2A562 (Ki)
620a (EC50)
18%a (
Emax)
5-HT2C3,130 (Ki)
2,400a (EC50)
76%a (
Emax)
SERTTooltip Serotonin transporter1,180 (Ki)
2,120 (IC50)
Notes: The smaller the value, the more avidly the drug interacts with the site.Footnotes:a = Stimulation ofIP1Tooltip inositol phosphate formation.Sources:[2]

Based on limited evidence, 5-MeO-DBT acts as anon-selectiveserotonin receptor agonist with the highestpotency andefficacy at the5-HT1A receptor.[2] It has a similar potency to5-MeO-MiPT for this target.[2] The substance, unlike many othersubstituted tryptamines, acts as a very weak and low efficacypartial agonist for the5-HT2A receptor.[2] Among the group of related tryptamineanalogues it also displayed the lowest efficacy for the5-HT2C receptor.[2]

5-MeO-DBT decreasedlocomotor activity and failed to substitute for thediscriminative stimulus effects ofDOM in rodentdrug discrimination tests.[5]

Chemistry

[edit]

Analogues

[edit]

Analogues of 5-MeO-DBT includedibutyltryptamine (DBT),4-HO-DBT,5-MeO-DMT,5-MeO-DET,5-MeO-DPT,5-MeO-DiPT, and5-MeO-DALT, among others.[1]

5-MeO-DsBT

[edit]

5-MeO-DsBT is a notableskeletal isomer of 5-MeO-DBT.[1] It was very briefly mentioned inAlexander Shulgin's bookTiHKAL (Tryptamines I Have Known and Loved), but was described as an unknown compound.[1] Relatedly, its dose andduration were not described.[1]

History

[edit]

5-MeO-DBT was first described in the literature byAlexander Shulgin in his 1997 bookTiHKAL (Tryptamines I Have Known and Loved).[1]

Society and culture

[edit]

Legal status

[edit]

United States

[edit]
Alabama
[edit]

5-MeO-DBT was made schedule I at the state level inAlabama on September 13, 2024.[4]

See also

[edit]

References

[edit]
  1. ^abcdefghijShulgin A,Shulgin A (September 1997).TiHKAL: The Continuation.Berkeley, California:Transform Press.ISBN 0-9630096-9-9.OCLC 38503252.https://isomerdesign.com/pihkal/read/tk/36
  2. ^abcdefghKozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, Schmachtenberg JL, et al. (April 2023)."Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter".The Journal of Pharmacology and Experimental Therapeutics.385 (1):62–75.doi:10.1124/jpet.122.001454.PMC 10029822.PMID 36669875.
  3. ^"Analytical Report. 5-MeO-DBT"(PDF). Slovenia: Nacionalni Forenzični Laboratorij. 10 March 2021.
  4. ^ab"Controlled Substances List"(PDF).www.alabamapublichealth.gov.
  5. ^abHill RD, Shetty RA, Sumien N, Priddy J, Forster MJ, Gatch MB (September 2025)."Behavioral effects of three synthetic tryptamine derivatives in rodents".Journal of Psychopharmacology.39 (9):1007–1013.doi:10.1177/02698811251330737.ISSN 0269-8811.PMID 40183394.

External links

[edit]
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=5-MeO-DBT&oldid=1322811144"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp